2022
Gender differences among persons entering medication treatment for opioid use disorder in the community
Di Paola A, Taweh N, Biondi BE, Forray A, Frank CA, Shaw A, Springer SA. Gender differences among persons entering medication treatment for opioid use disorder in the community. American Journal On Addictions 2022, 31: 390-395. PMID: 35652902, PMCID: PMC9463117, DOI: 10.1111/ajad.13304.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersQuality of lifeDSM-5 diagnosisPosttraumatic stress disorderOpioid relapseMedication useMedication historyMedication treatmentPsychiatric comorbidityPsychiatric medicationsHigh riskMOUDDepression severityGreater prevalenceGender differencesBaseline assessmentPsychological QoL.Disorder screeningStress disorderMultidisciplinary programGeneralized anxietyWomenMedicationsDisordersSupport Models for Addiction Related Treatment (SMART) for pregnant women: Study protocol of a cluster randomized trial of two treatment models for opioid use disorder in prenatal clinics
Forray A, Mele A, Byatt N, Tobon A, Gilstad-Hayden K, Hunkle K, Hong S, Lipkind H, Fiellin DA, Callaghan K, Yonkers KA. Support Models for Addiction Related Treatment (SMART) for pregnant women: Study protocol of a cluster randomized trial of two treatment models for opioid use disorder in prenatal clinics. PLOS ONE 2022, 17: e0261751. PMID: 35025898, PMCID: PMC8758001, DOI: 10.1371/journal.pone.0261751.Peer-Reviewed Original ResearchConceptsOpioid use disorderPregnant womenUse disordersPrenatal clinicsClinical trialsReproductive health cliniciansCollaborative care approachTRIAL REGISTRATION NUMBERCommunity Healthcare OutcomesMatched-pair clusterPatient treatment engagementTreatment modelObstetric providersOUD treatmentPrimary outcomeObstetrical providersPostpartum womenHealth cliniciansCare approachRegistration numberTreatment engagementRelated treatmentsHealthcare outcomesTrialsWomen
2021
Gender Differences among Criminal Justice-Involved Persons Living with HIV Interested in Extended-Release Naltrexone Treatment
Biondi BE, Frank CA, Forray A, Springer SA. Gender Differences among Criminal Justice-Involved Persons Living with HIV Interested in Extended-Release Naltrexone Treatment. Substance Abuse 2021, 42: 905-911. PMID: 33750285, PMCID: PMC8455717, DOI: 10.1080/08897077.2021.1900984.Peer-Reviewed Original ResearchConceptsSubstance use disordersOpioid use disorderMedication treatmentUse disordersAlcohol use disorderMental health severityXR-NTXAntiretroviral therapyDouble-blind placebo-controlled trialExtended-release naltrexone treatmentExtended-release naltrexonePlacebo-controlled trialCriminal justice-involved personsHealth severityGender differencesCocaine use disorderDrug use severityJustice-involved personsClinical characteristicsART adherenceNaltrexone treatmentTreatment outcomesHigh prevalenceCocaine useHIVMaternal opioid use disorder: Placental transcriptome analysis for neonatal opioid withdrawal syndrome
Radhakrishna U, Nath SK, Vishweswaraiah S, Uppala LV, Forray A, Muvvala SB, Mishra NK, Southekal S, Guda C, Govindamangalam H, Vargas D, Gardella WG, Crist RC, Berrettini WH, Metpally RP, Bahado-Singh RO. Maternal opioid use disorder: Placental transcriptome analysis for neonatal opioid withdrawal syndrome. Genomics 2021, 113: 3610-3617. PMID: 34352367, DOI: 10.1016/j.ygeno.2021.08.001.Peer-Reviewed Original ResearchConceptsNeonatal opioid withdrawal syndromeOpioid withdrawal syndromeWithdrawal syndromePrenatal opioid exposureOpioid use disorderPlacentas of infantsPlacental tissue samplesP-valueIngenuity Pathway AnalysisOpioid exposureUse disordersUnexposed controlsFDR p-valueGenes CYP1A1Tissue samplesSyndromePathway analysisCYP1A1NewbornsInfantsEtiologyApoBPlacentaGenesGRIN2AThe Collision of Mental Health, Substance Use Disorder, and Suicide
Forray A, Yonkers KA. The Collision of Mental Health, Substance Use Disorder, and Suicide. Obstetrics And Gynecology 2021, 137: 1083-1090. PMID: 33957654, DOI: 10.1097/aog.0000000000004391.Peer-Reviewed Original ResearchConceptsRisk of suicideSubstance use disordersUse disordersMental healthPerinatal periodSuicidal thoughtsReproductive health care clinicsSevere perinatal depressionHealth care clinicsCause of deathWomen's mental healthPerinatal depressionCare clinicsPerinatal womenPregnant womenDepressive episodeReproductive yearsPsychiatric illnessAmerican CollegePsychiatric disordersCareful monitoringPsychiatric conditionsSuicide attemptsChildhood adversitySuicide prevention
2020
Substance Use Disorder Detection Rates Among Providers of General Medical Inpatients
Serowik KL, Yonkers KA, Gilstad-Hayden K, Forray A, Zimbrean P, Martino S. Substance Use Disorder Detection Rates Among Providers of General Medical Inpatients. Journal Of General Internal Medicine 2020, 36: 668-675. PMID: 33111239, PMCID: PMC7947066, DOI: 10.1007/s11606-020-06319-7.Peer-Reviewed Original ResearchConceptsSubstance use disordersUse disordersMedical inpatientsPatient characteristicsMedical recordsGeneral medical inpatient unitsPatient self-report questionnairesGeneral medical inpatientsMedical inpatient unitsOpioid use disorderDrug use disordersNicotine use disorderPatients' medical recordsCannabis use disorderLarge teaching hospitalAlcohol use disorderDetection rateCocaine use disorderWhite patientsBlack patientsFemale patientsHispanic patientsFormal screeningInpatient providersTeaching hospital
2019
Opioid Use in Pregnancy
Tobon AL, Habecker E, Forray A. Opioid Use in Pregnancy. Current Psychiatry Reports 2019, 21: 118. PMID: 31734808, PMCID: PMC10296780, DOI: 10.1007/s11920-019-1110-4.Peer-Reviewed Original ResearchConceptsNeonatal opioid withdrawal syndromeOpioid use disorderOpioid exposureOpioid useMajor public health problemNeonatal adverse outcomesOpioid withdrawal syndromeStandard of carePublic health problemTerms of incidenceIllicit drug useSignificant adverse effectsMaintenance therapyPerinatal outcomesPregnancy outcomesRecent longitudinal studiesWithdrawal syndromeFetal effectsPregnant womenAdverse outcomesLong-term effectsUse disordersDrug useHealth problemsBrain morphology
2014
Progesterone for the reduction of cocaine use in post-partum women with a cocaine use disorder: a randomised, double-blind, placebo-controlled, pilot study
Yonkers KA, Forray A, Nich C, Carroll KM, Hine C, Merry BC, Shaw H, Shaw J, Sofuoglu M. Progesterone for the reduction of cocaine use in post-partum women with a cocaine use disorder: a randomised, double-blind, placebo-controlled, pilot study. The Lancet Psychiatry 2014, 1: 360-367. PMID: 25328863, PMCID: PMC4199242, DOI: 10.1016/s2215-0366(14)70333-5.Peer-Reviewed Original ResearchCocaine use disorderCocaine usePostpartum womenPost trialUse disordersPlacebo-controlled pilot trialOral micronized progesteronePositive urine testPost-partum womenGroup differencesSelf-reported daysMultiple brain functionsUse of cocaineMicronized progesteroneObstetrical clinicTherapeutic breakProgesterone replacementAdverse eventsUS National InstitutesProgesterone treatmentUrine testsPilot trialRate of submissionStudy biostatisticianProgesterone